Symposium

IBD, IL-23, and Inflammation, Oh My! Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD

Launch Date
02/06/2025 at 09:30 pm EST
Credit Amount
1.5
Credit Expires
02/06/2025

Faculty

Corey A. Siegel, MD, MS
Moderator
Director, Center for Digestive Health
Section Chief, Gastroenterology and Hepatology
Dartmouth Hitchcock Medical Center
Constantine and Joyce Hampers Professor of Medicine
Geisel School of Medicine at Dartmouth
Hanover, NH
Bincy P. Abraham, MD, MS, AGAF, FACG, FASGE, FCCF
Professor of Clinical Medicine, Houston Methodist Academic Institute
Professor of Clinical Medicine, Weill Cornell Medical College
Adjunct Professor of Clinical Education, Texas A&M University, College of Medicine
Director, Gastroenterology Fellowship Program, Houston Methodist
Distinguished Professor and Director, Underwood Center - Fondren Inflammatory Bowel Disease Program
Houston Methodist Gastroenterology Associates
Houston, TX
Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN
Inflammatory Bowel Disease Advanced Practice Nurse
Manager of Gastroenterology Advanced Practice Provider Services
The University of Chicago Medicine
Chicago, IL
Uma Mahadevan, MD
Lynne and Marc Benioff Professor of Gastroenterology
Director, Colitis and Crohn’s Disease Center
University of California San Francisco
San Francisco, CA
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn’s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active driver of IBD pathogenesis, making the IL-23/Th-17 inflammatory signaling axis a promising therapeutic target. Monoclonal antibodies (mAbs) have rapidly emerged at the forefront of anti-IL-23 targeted therapies, with structural differences between agents yielding unique clinical profiles that impact the durability of patient outcomes. In collaboration with a multidisciplinary care team, clinicians must understand how to tailor decision-making to the evolving science of cytokine-targeting therapies and the individual needs of patients with IBD.

In this CME Outfitters live symposium, expert faculty will instruct learners on the role of pro-inflammatory cytokines in the pathogenesis of IBD. Learners will be guided on the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis and how to appraise the clinical implications of anti-IL-23 agents used in the treatment of IBD. Faculty will model the development of individualized treatment plans for patients with IBD that are eligible for treatment with an IL-23-targeted agent.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Identify the role of pro-inflammatory cytokines in driving inflammation in the pathogenesis of IBD
  • Evaluate the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis
  • Appraise the clinical implications of anti-IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23-producing cells
  • Develop individualized treatment plans for patients with IBD that are eligible for treatment with an IL-23-targeted agent

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

Gastroenterologists, gastroenterology fellows/trainees, physician associates (PAs), nurse practitioners (NPs), and nurses

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Physician Assistants (AAPA): 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:

Dr. Siegel reports the following financial relationships:

Advisory Board: AbbVie Inc.; Bristol Myers Squibb Company; Buhlmann; Janssen Pharmaceuticals, Inc.; Lilly; Napo Therapeutics; Pfizer Inc.; Prometheus Biosciences, Inc.; Roivant Sciences; Takeda Pharmaceuticals U.S.A., Inc.; and Trellus Health Inc.

Consultant: AbbVie Inc.; Boomerang; Bristol Myers Squibb Company; Buhlmann; Janssen Pharmaceuticals, Inc.; Pfizer Inc; Prometheus Biosciences, Inc.; Prometheus Labs; and Takeda Pharmaceuticals U.S.A., Inc.

Grants: AbbVie Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer Inc.

Other financial or material support: Dr. Corey Siegel is co-founder of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.

Dr. Abraham reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb; Celltrion Inc.; Johnson & Johnson; Lilly; Medtronic; Pfizer Inc.; Prometheus Laboratories; Samsung Bioepis; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc.; Bristol Myers Squibb; Johnson & Johnson; Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Ms. Kametas reports the following financial relationships:

Advisory Board: Lilly and Pfizer Inc.

Consultant: TKG Therapeutics, Inc.

Grants: GI Research Foundation

Speakers Bureau: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Pfizer Inc.

Dr. Mahadevan reports the following financial relationships:

Advisory Board: Data Safety Monitoring Board (DSMB): Merck & Co., Inc.

Consultant: AbbVie Inc.; Bristol Myers Squibb; Boehringer Ingelheim; Celltrion Inc; Enveda Biosciences; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc; Protagonist Therapeutics Inc.; Rani Therapeutics; Roivant Sciences; and Takeda Pharmaceuticals U.S.A., Inc.

Grants: The Leona M. and Harry B. Helmsley Charitable Trust

The following individuals have no financial relationships to disclose:

Thai Nguyen, MD, MHA (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Chelsey Goins, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MM-148-020625-01

IBD, IL-23, and Inflammation, Oh My! Following the Yellow Brick Road in Using IL-23 Targeted Therapies in Managing IBD
Event Date: 02/06/2025 at 09:30 pm EST
Register